NLRP3 and acute myeloid leukemia: Additionally, treatment of MOLM-13, MV4-11, OCI-AML3 and THP-1 cells (AML patient-derived cell lines) with the NLRP3 inhibitor CP-456,773 induced significantly higher phosphorylation of eIF2α compared to their untreated counterparts (Fig. 3F, Suppl.